Wedbush Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and lowers the price target from $8 to $7.
Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and lowers the price target from $8 to $7.
